Features of Anemia Pathogenesis in Patients with Chronic Hepatitis C, Receiving Combination Antiviral Therapy
The use of combination antiviral therapy enables to achieve sustained virologic response in patients with chronic hepatitis C, but in some patients side effects occur during treatment. A special place among the undesirable manifestations of specific therapy for chronic hepatitis C take hematologic syndromes. In this paper we study some features of the pathogenesis of anemia that develops in patients with chronic hepatitis C receiving antiviral drugs.
Full Text:PDF (Русский)
Berry L. Predictors of hepatitis C treatment response: what's new? / L. Berry, W. Irving // Expert Review of Anti-infective Therapy. — 2014. — Vol. 12, № 2. — P. 183-191.
Flisiak R. Emerging treatments for hepatitis C / R. Flisiak,
J. Jaroszewicz, A. Parfieniuk-Kowerda // Expert Opinion on Emerging Drugs. — 2013. — Vol. 18, № 4. — P. 461-475.
Hashemi N. Safety of peginterferon in the treatment of chronic hepatitis C / N. Hashemi, S. Rossi, V.J. Navarro, S.K. Herrine // Expert Opinion on Drug Safety. — 2008. — Vol. 7, № 6. — P. 771-781.
Loustaud-Ratti V. Ribavirin in chronic hepatitis C: past and future / V. Loustaud-Ratti, A. Rousseau, P. Marquet, F. Denis,
S. Alain // Expert Review of Anti-infective Therapy. — 2009. — Vol. 7, № 3. — P. 249-253.
Suarez A. Desired Social Distance From People Who Have Hepatitis C Virus: An Exploration Among Staff in Health Care, Dentistry, Drug Treatment, and Tattoo/Body Piercing / A. Suarez,
D. Redmond // Substance Use & Misuse. — 2014. — Vol. 49, № 4. — P. 466-474.
Toyoda H. Pharmacotherapy of chronic hepatitis C virus infection — the IDEAL trial: ‘2b or not 2b (=2a), that is the question’ / H. Toyoda, T. Kumada // Expert Opinion on Pharmacotherapy. — 2009. — Vol. 10, № 17. — Р. 2845-2857.
- There are currently no refbacks.
Copyright (c) 2016 ACTUAL INFECTOLOGY
This work is licensed under a Creative Commons Attribution 4.0 International License.
© Publishing House Zaslavsky, 1997-2017